PT-141 vs GHRP-6
A comprehensive, data-driven comparison of PT-141 (Bremelanotide) and GHRP-6 (Growth Hormone Releasing Peptide-6). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | PT-141 Bremelanotide, Vyleesi | GHRP-6 Growth Hormone Releasing Peptide-6 |
|---|---|---|
| FDA Status | FDA Approved | Not submitted |
| Category | Sexual Health | Growth Hormone |
| Primary Use | Hypoactive sexual desire disorder (HSDD) in women | Growth hormone optimization |
| Weight Loss % | N/A | N/A |
| Monthly Cost | $800 - $1,200/mo | $35 - $70/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 1.75mg as needed, at least 45 min before activity | 100-300mcg 2-3x daily |
| Frequency | As needed | Daily |
| Mechanism | Melanocortin receptor agonist that activates central nervous system pathways involved in sexual arousal | First-generation growth hormone secretagogue that stimulates GH release and increases appetite via ghrelin mimicry |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | High | Emerging |
| Clinical Trial Phase | Approved | N/A |
Key Differences
- 1PT-141 is FDA-approved, while GHRP-6 is currently not submitted.
- 2GHRP-6 is generally more affordable ($35 - $70/mo) compared to PT-141 ($800 - $1,200/mo).
- 3PT-141 is dosed as needed, while GHRP-6 is daily.
- 4PT-141 has high-quality evidence, while GHRP-6 has emerging-quality evidence.
- 5They belong to different categories: PT-141 (Sexual Health) vs GHRP-6 (Growth Hormone).
Which Is Better For...
PT-141
Those seeking an FDA-approved treatment with established safety data
GHRP-6
More budget-friendly option with lower monthly costs
PT-141
More convenient dosing schedule (as needed)
PT-141
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| PT-141 | $800 - $1,200/mo | FDA Approved | Cosette Pharmaceuticals (Covis Pharma) |
| GHRP-6 | $35 - $70/mo | Not submitted | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
PT-141 works via Melanocortin receptor agonist that activates central nervous system pathways involved in sexual. GHRP-6 works via First-generation growth hormone secretagogue that stimulates GH release and increases appetite via. They differ in FDA approval status, efficacy data, and cost.
PT-141 typically costs $800 - $1,200/mo, while GHRP-6 costs $35 - $70/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
PT-141 is FDA-approved. GHRP-6 is not FDA-approved (Not submitted). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of PT-141 include Nausea, Flushing, Injection site reactions. Common side effects of GHRP-6 include Significant increase in appetite, Water retention, Tingling or numbness. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
PT-141 (Bremelanotide) is an FDA-approved peptide medication marketed as Vyleesi for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors like Viagra, PT-14...
View Full PT-141 GuideGHRP-6 is a synthetic hexapeptide and one of the first growth hormone releasing peptides developed. It stimulates GH secretion by activating the ghrelin receptor. Unlike later-generation peptides like...
View Full GHRP-6 GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between PT-141 and GHRP-6 should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.